Tuberculosis vaccine - Antigenics

Drug Profile

Tuberculosis vaccine - Antigenics

Latest Information Update: 05 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antigenics
  • Developer Antigenics; Brigham and Womens Hospital
  • Class Antituberculars; Recombinant fusion proteins; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Tuberculosis

Most Recent Events

  • 05 Sep 2006 Discontinued - Preclinical for Tuberculosis in USA (Injection)
  • 27 Aug 2001 Aquila Biopharmaceuticals has been integrated into Antigenics
  • 01 Dec 2000 Aquila Biopharmaceuticals has been acquired by Antigenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top